Avid Bioservices, Inc. (CDMO) 2017年年度报告「NASDAQ」.pdf

《Avid Bioservices, Inc. (CDMO) 2017年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Avid Bioservices, Inc. (CDMO) 2017年年度报告「NASDAQ」.pdf（162页珍藏版）》请在三个皮匠报告上搜索。

1、 Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended April 30,2017ORo TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EX

2、CHANGE ACT OF 1934For the transition period from _to _Commission file number:001-32839PEREGRINE PHARMACEUTICALS,INC.(Exact name of Registrant as specified in its charter)Delaware95-3698422(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)14282 Franklin

3、Avenue,Tustin,California92780(Address of principal executive offices)(Zip Code)(714)508-6000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of Each ClassName of Each Exchange on Which RegisteredCommon Stock($0.001 par value per share)

4、Preferred Stock Purchase Rights10.50%Series E Convertible Preferred Stock($0.001 par value per share)The NASDAQ Stock Market LLC The NASDAQ Stock Market LLCSecurities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defin

5、ed in Rule 405 of the Securities Act.Yes o No xIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Securities Act.Yes o No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15

6、(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No oIndicate by check mark whether the registrant has submitted electro